Treatment
Treatment
6.1.1	Modality of initial treatment	Dropdown 1, Resection|2, Transplantation|3, Locoregional|4, Systemic
6.1.2	First HCC treatment type	Checkbox 1, rx_1type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_1type___2 Drug-eluting bead (DEB)-TACE|3, rx_1type___3 Radiofrequency ablation (RFA)|4, rx_1type___4 Irreversible electroporation|5, rx_1type___5 Percutaneous ethanol injection (PEI)|6, rx_1type___6 Hepatic resection|7, rx_1type___7 Microwave ablation|8, rx_1type___8 Medication|9, rx_1type___9 Stereotactic body ablation radiotherapy|10, rx_1type___10 Liver transplant|11, rx_1type___11 Selective internal radiation therapy (SIRT)|12, rx_1type___12 No treatment|13, rx_1type___13 Other {rx_1other}|14, rx_1type___14 Distant hepatic recurrence|15, rx_1type___15 None of the above
6.1.3	Medications	Checkbox 1, rx_medications___1 Sorafenib|2, rx_medications___2 Lenvima (Lenvatinib)|3, rx_medications___3 Atezolizumab|4, rx_medications___4 Others: please specify: {rx_medications_other}|5, rx_medications___5 Clinical trial medication: please specify: {rx_medications_clintrial}
6.1.4	Other medications	Text
6.1.5	Clinical trial medications	Text
6.1.6	Date of treatment 1	Date
6.1.7	Other	Text
6.1.8	Reason no treatment	Checkbox 1, rx_1notreat___1 Patient unable to tolerate treatment|2, rx_1notreat___2 Patient moved before treatment|3, rx_1notreat___3 Patient lost to follow-up|4, rx_1notreat___4 Patient died before treatment
6.1.9	Curative intent	Dropdown 1, Yes|2, No|-99, Unknown
6.1.10	Treatment response at time interval 1	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.11	Date of response assessment to treatment 1	Date
6.1.12	Date complete response confirmed	Date
6.1.13	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.14	Date of recurrence	Date
6.1.15	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.16	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.17	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.18	Where is the extrahepatic spread?	Text
6.1.19	Complications after initial treatment	Checkbox 1, rx_complications___1 Liver-related morbidity|2, rx_complications___2 Post-procedural infections|3, rx_complications___3 Post-procedural bleeding|4, rx_complications___4 Bile duct injury|5, rx_complications___5 Respiratory events|6, rx_complications___6 Local events|7, rx_complications___7 Other {comp1_other}
6.1.20	Other complications	Text
6.1.21	Secondary therapies	Checkbox 1, rx_2type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_2type___2 Drug-eluting bead (DEB)-TACE|3, rx_2type___3 Radiofrequency ablation (RFA)|4, rx_2type___4 Irreversible electroporation|5, rx_2type___5 Percutaneous ethanol injection (PEI)|6, rx_2type___6 Hepatic resection|7, rx_2type___7 Microwave ablation|8, rx_2type___8 Medication|9, rx_2type___9 Stereotactic body ablation radiotherapy|10, rx_2type___10 Liver transplant|11, rx_2type___11 Selective internal radiation therapy (SIRT)|12, rx_2type___12 No treatment|13, rx_2type___13 Other {rx_2other}|14, rx_2type___14 Distant hepatic recurrence|15, rx_2type___15 None of the above
6.1.22	Medications	Checkbox 1, rx_medications_2___1 Sorafenib|2, rx_medications_2___2 Lenvima (Lenvatinib)|3, rx_medications_2___3 Atezolizumab|4, rx_medications_2___4 Others: please specify: {rx_medications_other_2}|5, rx_medications_2___5 Clinical trial medication: please specify: {rx_medications_clintrial_2}
6.1.23	Other medications	Text
6.1.24	Clinical trial medications	Text
6.1.25	Date of treatment 2	Date
6.1.26	Other	Text
6.1.27	Reason no treatment	Checkbox 1, rx_2notreat___1 Patient unable to tolerate treatment|2, rx_2notreat___2 Patient moved before treatment|3, rx_2notreat___3 Patient lost to follow up|4, rx_2notreat___4 Patient died before treatment
6.1.28	Treatment response at time interval 2	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.29	Date of response assessment to treatment 2	Date
6.1.30	Date complete response confirmed	Date
6.1.31	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.32	Date of recurrence	Date
6.1.33	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.34	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.35	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.36	Where is the extrahepatic spread?	Text
6.1.37	Complications after second treatment	Checkbox 1, rx_complications_2___1 Liver-related morbidity|2, rx_complications_2___2 Post-procedural infections|3, rx_complications_2___3 Post-procedural bleeding|4, rx_complications_2___4 Bile duct injury|5, rx_complications_2___5 Respiratory events|6, rx_complications_2___6 Local events|7, rx_complications_2___7 Other {comp2_other}
6.1.38	Other complications	Text
6.1.39	Third therapies	Checkbox 1, rx_3type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_3type___2 Drug-eluting bead (DEB)-TACE|3, rx_3type___3 Radiofrequency ablation (RFA)|4, rx_3type___4 Irreversible electroporation|5, rx_3type___5 Percutaneous ethanol injection (PEI)|6, rx_3type___6 Hepatic resection|7, rx_3type___7 Microwave ablation|8, rx_3type___8 Medication|9, rx_3type___9 Stereotactic body ablation radiotherapy|10, rx_3type___10 Liver transplant|11, rx_3type___11 Selective internal radiation therapy (SIRT)|12, rx_3type___12 No treatment|13, rx_3type___13 Other {rx_3other}|14, rx_3type___14 Distant hepatic recurrence|15, rx_3type___15 None of the above
6.1.40	Medications	Checkbox 1, rx_medications_3___1 Sorafenib|2, rx_medications_3___2 Lenvima (Lenvatinib)|3, rx_medications_3___3 Atezolizumab|4, rx_medications_3___4 Others: please specify: {rx_medications_other_3}|5, rx_medications_3___5 Clinical trial medication: please specify: {rx_medications_clintrial_3}
6.1.41	Other medications	Text
6.1.42	Clinical trial medications	Text
6.1.43	Date of treatment 3	Date
6.1.44	Other	Text
6.1.45	Reason no treatment	Checkbox 1, rx_3notreat___1 Patient unable to tolerate treatment|2, rx_3notreat___2 Patient moved before treatment|3, rx_3notreat___3 Patient lost to follow-up|4, rx_3notreat___4 Patient died before treatment
6.1.46	Treatment response at time interval 3	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.47	Date of response assessment to treatment 3	Date
6.1.48	Date complete response confirmed	Date
6.1.49	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.50	Date of recurrence	Date
6.1.51	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.52	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.53	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.54	Where is the extrahepatic spread?	Text
6.1.55	Complications after third treatment	Checkbox 1, rx_complications_3___1 Liver-related morbidity|2, rx_complications_3___2 Post-procedural infections|3, rx_complications_3___3 Post-procedural bleeding|4, rx_complications_3___4 Bile duct injury|5, rx_complications_3___5 Respiratory events|6, rx_complications_3___6 Local events|7, rx_complications_3___7 Other {comp3_other}
6.1.56	Other complications	Text
6.1.57	Did the patient receive additional treatments beyond those above?	yesno 1, Yes|0, No
6.1.58	Fourth therapy(ies)	Checkbox 1, rx_4type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_4type___2 Drug-eluting bead (DEB)-TACE|3, rx_4type___3 Radiofrequency ablation (RFA)|4, rx_4type___4 Irreversible electroporation|5, rx_4type___5 Percutaneous ethanol injection (PEI)|6, rx_4type___6 Hepatic resection|7, rx_4type___7 Microwave ablation|8, rx_4type___8 Medication|9, rx_4type___9 Stereotactic body ablation radiotherapy|10, rx_4type___10 Liver transplant|11, rx_4type___11 Selective internal radiation therapy (SIRT)|12, rx_4type___12 No treatment|13, rx_4type___13 Other {rx_4other}|14, rx_4type___14 Distant hepatic recurrence|15, rx_4type___15 None of the above
6.1.59	Other	Text
6.1.60	Medications	Checkbox 1, rx_medications_4___1 Sorafenib|2, rx_medications_4___2 Lenvima (Lenvatinib)|3, rx_medications_4___3 Atezolizumab|4, rx_medications_4___4 Others: please specify: {rx_medications_other_4}|5, rx_medications_4___5 Clinical trial medication: please specify: {rx_medications_clintrial_4}
6.1.61	Other medications	Text
6.1.62	Clinical trial medications	Text
6.1.63	Date of treatment 4	Date
6.1.64	Reason no treatment	Checkbox 1, rx_4notreat___1 Patient unable to tolerate treatment|2, rx_4notreat___2 Patient moved before treatment|3, rx_4notreat___3 Patient lost to follow up|4, rx_4notreat___4 Patient died before treatment
6.1.65	Treatment response at time interval 4	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.66	Date of response assessment to treatment 4	Date
6.1.67	Date complete response confirmed	Date
6.1.68	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.69	Date of recurrence	Date
6.1.70	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.71	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.72	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.73	Where is the extrahepatic spread?	Text
6.1.74	Complications after fourth treatment	Checkbox 1, rx_complications_4___1 Liver-related morbidity|2, rx_complications_4___2 Post-procedural infections|3, rx_complications_4___3 Post-procedural bleeding|4, rx_complications_4___4 Bile duct injury|5, rx_complications_4___5 Respiratory events|6, rx_complications_4___6 Local events|7, rx_complications_4___7 Other {comp4_other}
6.1.75	Other complications	Text
6.1.76	Fifth therapy(ies)	Checkbox 1, rx_5type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_5type___2 Drug-eluting bead (DEB)-TACE|3, rx_5type___3 Radiofrequency ablation (RFA)|4, rx_5type___4 Irreversible electroporation|5, rx_5type___5 Percutaneous ethanol injection (PEI)|6, rx_5type___6 Hepatic resection|7, rx_5type___7 Microwave ablation|8, rx_5type___8 Medication|9, rx_5type___9 Stereotactic body ablation radiotherapy|10, rx_5type___10 Liver transplant|11, rx_5type___11 Selective internal radiation therapy (SIRT)|12, rx_5type___12 No treatment|13, rx_5type___13 Other {rx_5other}|14, rx_5type___14 Distant hepatic recurrence|15, rx_5type___15 None of the above
6.1.77	Other	Text
6.1.78	Medications	Checkbox 1, rx_medications_5___1 Sorafenib|2, rx_medications_5___2 Lenvima (Lenvatinib)|3, rx_medications_5___3 Atezolizumab|4, rx_medications_5___4 Others: please specify: {rx_medications_other_5}|5, rx_medications_5___5 Clinical trial medication: please specify: {rx_medications_clintrial_5}
6.1.79	Other medications	Text
6.1.80	Clinical trial medications	Text
6.1.81	Date of treatment 5	Date
6.1.82	Reason no treatment	Checkbox 1, rx_5notreat___1 Patient unable to tolerate treatment|2, rx_5notreat___2 Patient moved before treatment|3, rx_5notreat___3 Patient lost to follow-up|4, rx_5notreat___4 Patient died before treatment
6.1.83	Treatment response at time interval 5	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.84	Date of response assessment to treatment 5	Date
6.1.85	Date complete response confirmed	Date
6.1.86	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.87	Date of recurrence	Date
6.1.88	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.89	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.90	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.91	Where is the extrahepatic spread?	Text
6.1.92	Complications after fifth treatment	Checkbox 1, rx_complications_5___1 Liver-related morbidity|2, rx_complications_5___2 Post-procedural infections|3, rx_complications_5___3 Post-procedural bleeding|4, rx_complications_5___4 Bile duct injury|5, rx_complications_5___5 Respiratory events|6, rx_complications_5___6 Local events|7, rx_complications_5___7 Other {comp5_other}
6.1.93	Other complications	Text
6.1.94	Sixth therapy(ies)	Checkbox 1, rx_6type___1 Conventional transarterial chemoembolization (cTACE)|2, rx_6type___2 Drug-eluting bead (DEB)-TACE|3, rx_6type___3 Radiofrequency ablation (RFA)|4, rx_6type___4 Irreversible electroporation|5, rx_6type___5 Percutaneous ethanol injection (PEI)|6, rx_6type___6 Hepatic resection|7, rx_6type___7 Microwave ablation|8, rx_6type___8 Medication|9, rx_6type___9 Stereotactic body ablation radiotherapy|10, rx_6type___10 Liver transplant|11, rx_6type___11 Selective internal radiation therapy (SIRT)|12, rx_6type___12 No Treatment|13, rx_6type___13 Other {rx_6other}|14, rx_6type___14 Distant hepatic recurrence|15, rx_6type___15 None of the above
6.1.95	Other	Text
6.1.96	Medications	Checkbox 1, rx_medications_6___1 Sorafenib|2, rx_medications_6___2 Lenvima (Lenvatinib)|3, rx_medications_6___3 Atezolizumab|4, rx_medications_6___4 Others: please specify: {rx_medications_other_6}|5, rx_medications_6___5 Clinical trial medication: please specify: {rx_medications_clintrial_6}
6.1.97	Other medications	Text
6.1.98	Clinical trial medications	Text
6.1.99	Date of treatment 6	Date
6.1.100	Reason No Treatment	Checkbox 1, rx_6notreat___1 Patient unable to tolerate treatment|2, rx_6notreat___2 Patient moved before treatment|3, rx_6notreat___3 Patient lost to follow up|4, rx_6notreat___4 Patient died before treatment
6.1.101	Treatment response at time interval 6	Dropdown 1, PD—progressive disease (an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started)|2, SD—stable disease (any cases that do not qualify for either partial response or progressive disease)|3, PR—partial response (at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions)|4, CR—complete response (disappearance of any intratumoral arterial enhancement in all target lesions)|-99, Not recorded/not measurable
6.1.102	Date of response assessment to treatment 6	Date
6.1.103	Date complete response confirmed	Date
6.1.104	If complete response, was there a recurrence?	Dropdown 1, Yes|2, No|-99, Unknown
6.1.105	Date of recurrence	Date
6.1.106	Type of recurrence: Liver	Dropdown 1, Yes|2, No|-99, Unknown
6.1.107	Liver recurrence	Dropdown 1, Local|2, Distant|3, Vascular invasion|-99, Unknown
6.1.108	Extrahepatic	Dropdown 1, Yes|2, No|-99, Unknown
6.1.109	Where is the extrahepatic spread?	Text
6.1.110	Complications after sixth treatment	Checkbox 1, rx_complications_6___1 Liver-related morbidity|2, rx_complications_6___2 Post-procedural infections|3, rx_complications_6___3 Post-procedural bleeding|4, rx_complications_6___4 Bile duct injury|5, rx_complications_6___5 Respiratory events|6, rx_complications_6___6 Local events|7, rx_complications_6___7 Other {comp5_other}
6.1.111	Other complications	Text
Form Status
6.2.1	Complete?	Dropdown 0, Incomplete|1, Unverified|2, Complete